Consideration in the evaluation of follow-up of resistant hypertension

Affiliations

Editorial

Decio Armanini et al. J Hypertens. 2024.

. 2024 Jan 1;42(1):56-57.

doi: 10.1097/HJH.0000000000003603. Epub 2023 Nov 30.

¹ Department of Medicine - Endocrinology Unit, Hospital-University of Padua, Padua, Italy.

No abstract available

Comment on

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial.
Peeters LEJ, Kappers MHW, Hesselink DA, van der Net JB, Hartong SCC, van de Laar R, Ezzahti M, van de Ven PJG, van der Meer IM, de Bruijne ELE, Kroon AA, Indhirajanti-Tomasoa S, van der Linde NAJ, Bahmany S, Boersma E, Massey EK, van Dijk L, van Gelder T, Koch BCP, Versmissen J. Peeters LEJ, et al. J Hypertens. 2024 Jan 1;42(1):169-178. doi: 10.1097/HJH.0000000000003585. Epub 2023 Oct 18. J Hypertens. 2024. PMID: 37796233 Free PMC article. Clinical Trial.

1. Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019; 124:1124–1140.
1. Davis SA, Feldman SR. Using hawthorne effects to improve adherence in clinical practice: 515 lessons from clinical trials. JAMA Dermatol 2013; 149:490–491.
1. Peeters LEJ, Kappers MHW, Hesselink DA, van der Net JB, Hartong SCC, van de Laar R, et al. Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial. J Hypertens 2024; 42:169–178.
1. Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am 2017; 101:229–245.
1. Shalaeva EV, Messerli FH. What is resistant arterial hypertension? Blood Press 2023; 32:2185457.